Arcturus Therapeutics Holdings Financial Statements (ARCT)
|
|
|
|
Report date
|
|
|
11.08.2025 |
12.11.2025 |
03.03.2026 |
07.05.2026 |
06.08.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
24.5 |
17.2 |
3.08 |
0.610 |
2.96 |
|
45.4 |
|
Operating Income, bln rub |
|
|
-11.6 |
-16.5 |
-31.3 |
-29.8 |
-25.5 |
|
-89.2 |
|
EBITDA, bln rub |
? |
|
-8.40 |
-12.7 |
-20.1 |
-26.3 |
-23.8 |
|
-72.8 |
|
Net profit, bln rub |
? |
|
-9.18 |
-13.4 |
-29.1 |
-27.0 |
-23.8 |
|
-78.7 |
|
|
OCF, bln rub |
? |
|
-5.76 |
-17.2 |
-16.2 |
-19.4 |
-19.9 |
|
-58.6 |
|
CAPEX, bln rub |
? |
|
0.000 |
0.181 |
0.138 |
0.000 |
0.000 |
|
0.319 |
|
FCF, bln rub |
? |
|
-5.76 |
-17.3 |
-16.4 |
-19.4 |
-19.9 |
|
-58.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
36.1 |
30.3 |
34.4 |
29.7 |
28.5 |
|
130.6 |
|
Cost of production, bln rub |
|
|
0.000 |
3.34 |
0.000 |
0.658 |
0.000 |
|
4.00 |
|
R&D, bln rub |
|
|
29.6 |
23.3 |
24.5 |
20.9 |
17.5 |
|
98.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
309.3 |
282.3 |
271.1 |
245.4 |
224.3 |
|
245.4 |
|
Net Assets, bln rub |
? |
|
231.1 |
224.6 |
214.0 |
191.4 |
171.8 |
|
191.4 |
|
Debt, bln rub |
|
|
27.0 |
26.0 |
25.0 |
24.0 |
22.9 |
|
19.7 |
|
Cash, bln rub |
|
|
196.5 |
180.4 |
230.9 |
211.4 |
191.5 |
|
211.4 |
|
Net debt, bln rub |
|
|
-169.5 |
-154.4 |
-205.9 |
-187.4 |
-168.6 |
|
-191.7 |
|
|
Ordinary share price, rub |
|
|
13.0 |
18.4 |
6.13 |
7.72 |
6.72 |
|
7.53 |
|
Number of ordinary shares, mln |
|
|
27.1 |
27.2 |
27.4 |
28.4 |
28.4 |
|
28.4 |
|
|
Market cap, bln rub |
|
|
353 |
501 |
168 |
219 |
191 |
|
214 |
|
EV, bln rub |
? |
|
183 |
347 |
-38 |
32 |
22 |
|
22 |
|
Book value, bln rub |
|
|
231 |
225 |
214 |
191 |
172 |
|
191 |
|
|
EPS, rub |
? |
|
-0.34 |
-0.49 |
-1.06 |
-0.95 |
-0.84 |
|
-2.77 |
|
FCF/share, rub |
|
|
-0.21 |
-0.64 |
-0.60 |
-0.68 |
-0.70 |
|
-2.07 |
|
BV/share, rub |
|
|
8.52 |
8.26 |
7.81 |
6.73 |
6.04 |
|
6.73 |
|
|
EBITDA margin, % |
? |
|
-34.3% |
-74.0% |
-653.7% |
-4 312% |
-803.8% |
|
-160.5% |
|
Net margin, % |
? |
|
-37.5% |
-78.4% |
-943.8% |
-4 420% |
-803.8% |
|
-173.5% |
|
FCF yield, % |
? |
|
-18.5% |
-11.7% |
-44.5% |
-26.8% |
-38.2% |
|
-27.5% |
|
ROE, % |
? |
|
-26.0% |
-29.7% |
-30.7% |
-41.1% |
-54.3% |
|
-41.1% |
|
ROA, % |
? |
|
-19.5% |
-23.6% |
-24.3% |
-32.1% |
-41.6% |
|
-32.1% |
|
|
P/E |
? |
|
-5.87 |
-7.51 |
-2.55 |
-2.79 |
-2.05 |
|
-2.72 |
|
P/FCF |
|
|
-5.42 |
-8.54 |
-2.25 |
-3.73 |
-2.61 |
|
-3.63 |
|
P/S |
? |
|
3.10 |
5.44 |
2.26 |
4.84 |
8.02 |
|
4.72 |
|
P/BV |
? |
|
1.53 |
2.23 |
0.78 |
1.15 |
1.11 |
|
1.12 |
|
EV/EBITDA |
? |
|
-3.07 |
-5.23 |
0.66 |
-0.47 |
-0.27 |
|
-0.31 |
|
Debt/EBITDA |
|
|
2.83 |
2.33 |
3.60 |
2.78 |
2.03 |
|
2.63 |
|
|
R&D/CAPEX, % |
|
|
|
12 854% |
17 780% |
|
|
|
30 831% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
1.06% |
4.47% |
0.00% |
0.00% |
|
0.70% |
|
| Arcturus Therapeutics Holdings shareholders |
